Efficacy of halobetasol and tazarotene lotion for plaque psoriasis utilizing IGAxBSA measurements

被引：0

作者：

Blauvelt, Andrew ^{[1
]}

Green, Lawrence J. ^{[2
]}

Bagel, Jerry ^{[3
]}

Lin, Tina ^{[4
]}

Martin, Gina ^{[5
]}

Israel, Robert ^{[5
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] George Washington Univ, Sch Med, Dept Dermatol, Washington, DC USA

[3] Psoriasis Treatment Ctr Cent New Jersey, East Windsor, NJ USA

[4] Ortho Dermatol, Bridgewater, NJ USA

[5] Bausch Hlth, Bridgewater, NJ USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

9785

引用

页码：AB201 / AB201

页数：1

共 50 条

[21] Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion
Desai, Seemal R.
Alexis, Andrew F.
Jacobson, Abby
JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (10) : 1000 - 1004
[22] Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities
Bhatia, Neal D.
Vlahovic, Tracey C.
Green, Lawrence G.
Martin, Gina
Lin, Tina
JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (10) : 1029 - 1036
[23] Fixed-Combination Halobetasol Propionate and Tazarotene Topical Lotion Decreases Interleukin-17A Levels in Psoriasis
Draelos, Zoe
Draelos, Matthew
Lin, Tina
Jacobson, Abby
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB169 - AB169
[24] Tazarotene gel: Efficacy and safety in plaque psoriasis - Discussion
SchaeferKorting
Chandraratna
Orfanos, C
Greaves, M
Duvic
Aal, A
Marks
Fattah, A
Munroe, C
Weinstein
Freeman, K
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (02) : S39 - S40
[25] Long-term management of moderate-to-severe plaque psoriasis: Maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion
Gold, L. F. Stein
Lebwohl, M. G.
Bhatia, N.
Lin, T.
Pillai, R.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S82 - S82
[26] An Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis
Ozyurekoglu, Elif
Kircik, Leon H.
JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (11) : 1191 - 1194
[27] Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area
Tanghetti, Emil A.
Bhatia, Neal
Drew, Scott
Jacobson, Abby
JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (08) : 829 - 836
[28] Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females
Gold, Linda Stein
Elewski, Boni
Draelos, Zoe
Jacobson, Abby
Lin, Tina
JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (05) : 504 - 514
[29] Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis
Adam, David N.
Bernasconi, Marie Y. Jablonski
Thoning, Henrik
Wu, Jashin J.
DERMATOLOGY AND THERAPY, 2022, 12 (11) : 2589 - 2600
[30] Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis
David N. Adam
Marie Y. Jablonski Bernasconi
Henrik Thoning
Jashin J. Wu
Dermatology and Therapy, 2022, 12 : 2589 - 2600

← 1 2 3 4 5 →